Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1378/chest.129.4.1113 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparative effectiveness of disease modifying antirheumatic drugs for patients with cardiac sarcoidosis.
Rheumatology (Oxford)
December 2024
Medical College of Wisconsin, Milwaukee, WI, USA.
Objectives: We aimed to evaluate the comparative efficacy of disease modifying antirheumatic drugs (DMARDs) for patients with cardiac sarcoidosis.
Methods: We performed a retrospective cohort study of new users of methotrexate, mycophenolate, or azathioprine for sarcoidosis using the US-based TriNetX electronic health records database from 2008-2023. Hazard ratios were calculated using inverse probability of treatment weighted Cox proportional hazards regressions to compare the efficacy of DMARDs with respect to delaying major adverse cardiac events among patients with cardiac sarcoidosis and preventing cardiac sarcoidosis from developing among patients with non-cardiac sarcoidosis.
Neuropsychiatric manifestations of sarcoidosis.
Ann Med
December 2025
Cardiac, Thoracic and Vascular, Sciences and Public Health, University of Padova School of Medicine and Surgery, Padua, Italy.
Background: There has been significant progress in understanding neurosarcoidosis (NS) as a distinct disorder, which encompasses a heterogeneous group of clinical and radiological alterations which can affect patients with systemic sarcoidosis or manifest isolated.
Rationale And Aim Of The Study: The healthcare challenges posed by NS and sarcoidosis in general extend beyond their physical symptoms and can include a variety of psychosocial factors, therefore the recognition of main neuropsychiatric symptoms can be useful to approach patients with NS. Methods: For this purpose, databases such as Pubmed, Medline and Pubmed Central (PMC) have been searched.
Preprocedural Screening Tool to Guide Nonpulmonary Vein Trigger Testing in First-Time Atrial Fibrillation Ablation.
Circ Arrhythm Electrophysiol
December 2024
Section of Cardiac Electrophysiology, Division of Cardiovascular Medicine, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia.
Background: Patients undergoing first-time atrial fibrillation (AF) ablation can benefit from targeting non-pulmonary vein (PV) triggers. Preprocedural identification of high-risk individuals can guide planning of ablation strategy. This study aimed to create a preprocedural screening tool to identify patients at risk of non-PV triggers during first-time AF ablation.
View Article and Find Full Text PDFMagnetic Resonance Imaging in the Assessment of the Risk of Sudden Death in Cardiac Sarcoidosis: What Is Extensive or Significant Late Gadolinium Enhancement?
Circ Arrhythm Electrophysiol
December 2024
Heart and Lung Center (P.P., J.L., D.V., H.M., P.S., H.-K.N., M.K.).
Background: Cardiac sarcoidosis involves a significant but difficult-to-define risk of sudden cardiac death (SCD). Current guidelines recommend consideration of an implantable cardioverter defibrillator for patients with extensive or significant myocardial late gadolinium enhancement (LGE) on cardiac magnetic resonance imaging. However, extensive/significant LGE is not defined.
View Article and Find Full Text PDFAtorvastatin in Severity-stratified Pulmonary Sarcoidosis: A Phase II Randomized Controlled Trial.
Am J Respir Crit Care Med
December 2024
NIH, National Heart, Lung, and Blood Institute, Bethesda, Maryland, United States.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!